Skip to content
GenoLensGenoLens

FGD1

Chr Xp11.22

FYVE, RhoGEF and PH domain containing 1

Aliases:
ZFYVE3
MANE:
ENST00000375135.4

Annotations refreshed 10 hours ago.

Predicted protein structure

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

  • Clefting

    X-LINKED: hemizygous mutation in males, biallelic mutations in females
  • DDG2P

    X-LINKED: hemizygous mutation in males, biallelic mutations in females
  • Fetal anomalies

    X-LINKED: hemizygous mutation in males, biallelic mutations in females
  • Intellectual disability

    X-LINKED: hemizygous mutation in males, biallelic mutations in females
  • IUGR and IGF abnormalities

    X-LINKED: hemizygous mutation in males, biallelic mutations in females
  • Limb disorders

    X-LINKED: hemizygous mutation in males, biallelic mutations in females
  • Monogenic short stature

    X-LINKED: hemizygous mutation in males, biallelic mutations in females
  • Osteogenesis imperfecta

Disease associations (Open Targets)

  • Aarskog-Scott syndrome, X-linked

    0.81
  • faciodigitogenital syndrome

    0.68
  • hereditary disease

    0.53
  • neurodegenerative disease

    0.46
  • Intellectual disability

    0.43
  • Abnormality of the skeletal system

    0.39
  • X-linked intellectual disability, Siderius type

    0.37
  • Neurodevelopmental delay

    0.34
  • Polyhydramnios

    0.34
  • syndromic X-linked intellectual disability Claes-Jensen type

    0.30

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

FYVE, RhoGEF and PH domain-containing protein 1

Activates CDC42, a member of the Ras-like family of Rho- and Rac proteins, by exchanging bound GDP for free GTP. Plays a role in regulating the actin cytoskeleton and cell shape

Data sources: HGNC (CC BY 4.0), AlphaFold (CC BY 4.0, Jumper et al. Nature 2021), Genomics England PanelApp (CC BY 4.0), ClinGen, Open Targets (CC0), UniProt.

Not for sole clinical decision-making. Always verify against primary sources.